Product
BMF-219
Aliases
Covalent Menin Inhibitor
4 clinical trials
29 indications
Indication
Type 2 Diabetes MellitusIndication
Lung CancerIndication
Pancreatic CancerIndication
Colorectal CancerIndication
NSCLCIndication
PDACIndication
Colorectal cancerIndication
Relapsed CancerIndication
Refractory CancerIndication
Stage III Pancreatic CancerIndication
Stage III Non-small Cell Lung CancerIndication
Stage III NSCLCIndication
Stage IV Non-Small Cell Lung CancerIndication
KRAS Mutation-Related TumorsIndication
Acute Myeloid LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
Acute Mixed-Phenotype LeukemiaIndication
CancerIndication
RefractoryIndication
ProgressionIndication
Diffuse Large B-Cell LymphomaIndication
Multiple MyelomaIndication
lymphomaIndication
Non-HodgkinIndication
Plasma CellIndication
multiple myelomaIndication
Chronic Lymphocytic LeukemiaIndication
Small Lymphocytic LymphomaIndication
Type 1 Diabetes MellitusClinical trial
A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, PK, and PD of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adults and Adults With T2DStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants With Type 1 Diabetes MellitusStatus: Recruiting, Estimated PCD: 2025-08-31